Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth阻断交叉通讯通路改变了胰腺癌的免疫细胞特征并抑制了肿瘤生长Cell Communication and SignalingIF8.92026-01-160OAAI
The Role of a Cholecystokinin Receptor Antagonist in the Management of Chronic Pancreatitis: A Phase 1 TrialPHARMACEUTICSIF5.52024-04-300OAAI
Implicating the cholecystokinin B receptor in liver stem cell oncogenesisAMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGYIF3.32024-03-010OA
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic SteatohepatitisCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-09-274OAAI
Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic ImpairmentPHARMACEUTICSIF5.52022-03-122OAAI
Cholecystokinin-B receptor mediates growth of hepatocellular carcinomaCANCER RESEARCHIF16.62020-08-150PRE
Cholecystokinin receptor antagonist decreases fibrosis in pancreatic cancer microenvironment to improve uptake and efficacy of chemotherapyCANCER RESEARCHIF16.62020-08-150PRE
Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastasesAMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGYIF3.32019-11-0110OAAI
Cholecystokinin receptor antagonist proglumide reverses nonalcoholic steatohepatitis and prevents hepatocellular carcinomaCANCER RESEARCHIF16.62019-07-010PRE